#bempegaldesleukin
Bempegaldesleukin
Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.
Wed 16th
Provided by Wikipedia
This keyword could refer to multiple things. Here are some suggestions:
0 searches
This keyword has never been searched before
This keyword has never been searched for with any other keyword.